Administration of DAB389IL-2 to patients with recalcitrant psoriasis: a double-blind, phase II multicenter trial
J Bagel, WT Garland, D Breneman, M Holick… - Journal of the American …, 1998 - Elsevier
Background: Current therapies for recalcitrant psoriasis focus on immunoregulation and
targeting of activated T-lymphocytes rather than keratinocytes. Previous studies with low
doses of the lymphocyte-selective fusion protein DAB389IL-2 have shown benefit to patients
with psoriasis. Objective: We examined the safety and efficacy of DAB 389IL-2 in 41
volunteers receiving more frequent and higher doses than in a previous trial. Methods:
Patients were randomized to receive either placebo or 5, 10, or 15 mg/kg daily of DAB 389IL …
targeting of activated T-lymphocytes rather than keratinocytes. Previous studies with low
doses of the lymphocyte-selective fusion protein DAB389IL-2 have shown benefit to patients
with psoriasis. Objective: We examined the safety and efficacy of DAB 389IL-2 in 41
volunteers receiving more frequent and higher doses than in a previous trial. Methods:
Patients were randomized to receive either placebo or 5, 10, or 15 mg/kg daily of DAB 389IL …
